Nectar Raises over $24M in Funding to Scale Personalized Allergy Care Platform Nationally

Investment from venture funds Juxtapose, Obvious Ventures, and Harmony Partners will help Nectar launch its comprehensive allergy care program nationwide. Nectar, an innovative and comprehensive allergy care platform, announced today its $16.5 million Series A round led by Harmony Partners, with meaningful participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with Founding CEO Kenneth Chahine, Ph.D. Nectar’s latest fundraising round, which builds on their March 2022 seed investment and brings total equity raised to over $24M, will allow the company to invest in three key areas in 2023: scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies. Nectar is the consumer-facing brand of Nectar Life Sciences, an allergy-focused healthcare holding company led by Dr. Chahine, one of the country’s leading entrepreneurial operators at the intersection of science and healthcare. Nectar launched in June 2022 with a mission to turn clinical research into personalized, accessible, and revolutionary allergy care and ultimately put an end to allergies. “Today, over 120 million people in the US suffer from allergic diseases, yet most consumers feel under-served and constrained with the therapies available to them,” said Nectar’s Dr. Chahine. “We’re proud to tackle this chronic illness head-on with transformativ...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT AAPRI Allergy Care Harmony Partners Health IT Funding Health IT Fundings Health IT Investment Imperial College London James Joaquin John Zwetchkenbaum M.D. Juxtapose Kari Nadeau M.D. Ph.D. Kenneth Source Type: blogs